Acute Myeloid Leukemia AML Market GRÖSSEN- UND MARKTANTEILSANALYSE - WACHSTUMSTRENDS UND PROGNOSEN (2024 - 2031)
Acute Myeloid Leukemia (AML) Market is segmented By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration (Oral, Intravenous), By End User (Hospitals, Specialty Clinics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Acute Myeloid Leukemia AML Market Size
Marktgröße in USD Bn
CAGR7.5%
| Studienzeitraum | 2024 - 2031 |
| Basisjahr der Schätzung | 2023 |
| CAGR | 7.5% |
| Marktkonzentration | Medium |
| Hauptakteure | Bristol-Myers Squibb, AbbVie, Pfizer, F. Hoffmann-La Roche, Novartis and Among Others. |
please let us know !
Acute Myeloid Leukemia AML Market Analysis
The Acute Myeloid Leukemia (AML) market is estimated to be valued at USD 1.613 billion in 2024 and is expected to reach USD 2.68 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
The growing geriatric population who are susceptible to develop AML combined with the rising demand for targeted drug therapy for better treatment outcomes are key factors expected to drive the growth of the AML market.